Trials / Unknown
UnknownNCT03427242
Apatinib for Advanced Biliary Carcinoma
A Phase II Study of Apatinib Treatment for Advanced Biliary Tract Carcinoma After Failure of the First-line Chemotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55 patients is planned for enrollment. The time for enrollment is from Nov 2017 to Nov 2020, the the follow-up will be ended after Nov 2021. Patients in the study would receive oral apatinib 500-750mg qd until progression of disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | oral apatinib 750mg qd |
Timeline
- Start date
- 2017-11-01
- Primary completion
- 2021-10-31
- Completion
- 2022-10-31
- First posted
- 2018-02-09
- Last updated
- 2018-02-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03427242. Inclusion in this directory is not an endorsement.